Summary
This prediction ended on 15.09.14 with a price of €3.06. With a performance of -1.16%, the SELL prediction for Evotec SE by mohabbatein was down slightly. mohabbatein has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Evotec SE | -3.440% | -3.440% | -50.962% | -72.257% |
iShares Core DAX® | 0.051% | 5.593% | 14.403% | 19.767% |
iShares Nasdaq 100 | 1.808% | 7.445% | 34.917% | 57.237% |
iShares Nikkei 225® | 2.181% | 2.815% | 11.116% | 8.873% |
iShares S&P 500 | 1.040% | 4.975% | 27.631% | 48.786% |
Comments by mohabbatein for this prediction
In the thread Evotec AG diskutieren
Studiendebakel
Die Aktienkurse der Biotechs leben von
a) dem Vertrauen der Anleger in die rosige Zukunft
b) von Meilensteinzahlungen für Forschungserfolge
c) von Auslizensierungsfantasien.
Alle 3 Punkte haben heute bei Evotec einen krachenden Dämpfer bekommen. Noch dazu auf höchst unappetitliche Art und Weise. Mittels Forschungsbetrug !?
SELL.